23 withdrawn. 23 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Withdrawn 23 |
| Phase 1 | 4 | Withdrawn 4 |
| Phase 3 | 2 | Withdrawn 2 |
Follow Depressive Disorder: new trials by email Literature Review of Depressive Disorder trials Research Report on Depressive Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Transcranial Magnetic Stimulation for Youth With Treatment-Resistant Major Depressive Disorder Intermittent theta burst repetitive transcranial magnetic stimulation (iTBS) - Major Depressive Disorder | Phase 2 | Withdrawn | National Institute of Mental Health (NIMH) | 2026-04-25 | 2026-04-28 | |
| N2O for Acute Suicidality and Depression in the ED Nitrous oxide gas for inhalation, Placebo - Suicidal Ideation, Major Depressive Disorder | Phase 2 | Withdrawn | University of Chicago | 2026-02-27 | 2026-03-04 | |
| The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case Series interpersonal psychotherapy (IPT), Ketamine - Postpartum Depression | Phase 2 / Phase 3 | Withdrawn | Washington University School of Medicine | 2025-10-15 | 2025-10-29 | |
| Repeated Neurocognitive Measurements in Depressed Patients Intravenous Ketamine - Depression, Unipolar | Phase 1 / Phase 2 | Withdrawn | Jay Fournier | 2025-05-01 | 2026-02-25 | |
| Psilocybin for Major Depressive Disorder Psilocybin - Major Depressive Disorder | Phase 2 | Withdrawn | Washington University School of Medicine | 2024-01-01 | 2024-07-25 | |
| PET Synaptogenesis After Psilocybin In DEpression Recovery Psilocybin - Major Depressive Disorder, Anhedonia | Phase 2 | Withdrawn | Washington University School of Medicine | 2023-07-01 | 2023-01-30 | |
| Effect of SSRIs on Response to Psilocybin Therapy Psilocybin - Depression, Major Depressive Disorder | Phase 2 | Withdrawn | Cybin Therapeutics Inc. | 2023-01-01 | 2023-07-06 | |
| The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD Psilocybin - Treatment-Resistant Major Depressive Disorder | Phase 2 | Withdrawn | Massachusetts General Hospital | 2022-09-15 | 2024-01-24 | |
| The Efficacy of Probiotic Compared With Placebo Commitment Therapy for Treatment of Major Depressive Disorder Probiotic, Placebo, Acceptance and commitment therapy (ACT) - Major Depressive Disorder | Phase 2 | Withdrawn | Min-Tze LIONG | 2021-10-01 | 2023-05-10 | |
| The Phosphodiesterase Inhibitor Tadalafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients Tadalafil 5Mg Tab, Placebo - Major Depressive Disorder | Phase 1 / Phase 2 | Withdrawn | Sadat City University | 2021-08-01 | 2025-07-14 | |
| Antidepressant Effects of Nitrous Oxide Nitrous oxide gas for inhalation, Placebo - Major Depressive Disorder, Treatment Resistant Depression | Phase 2 | Withdrawn | University of Chicago | 2021-06-30 | 2026-05-14 | |
| The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients Roflumilast 500Mcg Tab, Placebo - Major Depressive Disorder | Phase 1 / Phase 2 | Withdrawn | Sadat City University | 2021-02-01 | 2025-07-14 | |
| The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients Vildagliptin 50 MG, Escitalopram 20 mg - Major Depressive Disorder | Phase 1 / Phase 2 | Withdrawn | Sadat City University | 2020-05-01 | 2025-07-14 | |
| Neural and Antidepressant Effects of Propofol (Phase 2) Diprivan - Treatment Resistant Depression | Phase 2 / Phase 3 | Withdrawn | University of Utah | 2019-04-16 | 2019-12-18 | |
| Efficacy and Safety of TAK-653 in Treatment-Resistant Depression TAK-653, Placebo - Treatment-Resistant Depression | Phase 2 | Withdrawn | Millennium Pharmaceuticals, Inc. | 2018-02-15 | 2018-02-22 | |
| Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine Lithium, Placebo, Ketamine - Treatment Resistant Depression | Phase 2 | Withdrawn | William V. Bobo, M.D. | 2017-11-30 | 2018-08-16 | |
| Investigate Efficacy & Safety of RO4995819 vs. Placebo as Adjunct Tx in Patients w/Major Depressive Disorder RO4995819 - Depression, Major Depressive Disorder | Phase 2 | Withdrawn | Stanford University | 2012-09-01 | 2019-10-04 | |
| Effects of Seroquel XR on Sleep Architecture in Patients With Major Depressive Disorder Quetiapine Fumarate Extended Release - Major Depressive Disorder | Phase 2 | Withdrawn | Ewha Womans University | 2012-03-01 | 2015-08-07 | |
| Adjunctive Pregnenolone in Post-Traumatic Stress Disorder (PTSD) and Depression in Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans pregnenolone, placebo - Post-traumatic Stress Disorder, Major Depressive Disorder | Phase 2 | Withdrawn | US Department of Veterans Affairs | 2010-01-01 | 2014-10-27 | |
| rTMS for Adolescents and Young Adults TMS with Neurostar TMS Therapy System - Major Depressive Disorder | Phase 2 | Withdrawn | Johns Hopkins University | 2009-10-01 | 2013-04-04 |
Showing 20 of 23. Sign in to see all of them.
Depressive Disorder, Major (16) · Depression (8) · Depressive Disorder, Treatment-Resistant (6) · Mood Disorders (2) · Anhedonia (1) · Bipolar Disorder (1) · Depression, Postpartum (1) · Mental Disorders (1) · Rumination Syndrome (1) · Stress Disorders, Post-Traumatic (1) · Suicidal Ideation (1)
Mental Disorders (22) · Mood Disorders (21) · Behavior (8) · Behavioral Symptoms (8) · Bipolar and Related Disorders (1) · Digestive System Diseases (1) · Feeding and Eating Disorders (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1) · Neurologic Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Pregnancy Complications (1)
Psilocybin (4) · Ketamine (3) · Endothelium-Dependent Relaxing Factors (2) · Inhalation (2) · Nitrous Oxide (2) · 1-(benzofurazan-5-ylcarbonyl)piperidine (1) · AMPA receptor potentiator HBT1 (1) · Acceptance and Commitment Therapy (1) · Escitalopram (1) · Interpersonal Psychotherapy (1) · Lithium (1) · Lithium Carbonate (1) · Omacor (1) · Pregnenolone (1) · Probiotics (1)
Sadat City University (3) · Washington University School of Medicine (3) · University of Chicago (2) · Cybin Therapeutics Inc. (1) · Dennis Charney (1) · Ewha Womans University (1) · Jay Fournier (1) · Johns Hopkins University (1) · Massachusetts General Hospital (1) · Millennium Pharmaceuticals, Inc. (1) · Min-Tze LIONG (1) · National Institute of Mental Health (NIMH) (1) · Stanford University (1) · US Department of Veterans Affairs (1) · University Hospital, Strasbourg, France (1)
United States (12) · Egypt (3) · Australia (1) · Canada (1) · Malaysia (1) · South Korea (1)
Peter Nagele, MD, MSc (2) · Charles DeBattista, DMH, MD (1) · Daniel S Pine, M.D. (1) · David Monks, MBCHB (1) · Dennis S Charney, MD (1) · Ginger Nicol, MD (1) · Inkyoon Lyoo, MD, PhD, MMS (1) · Irving Reti, M.B.B.S (1) · Luke Woon Sy-Cherng, Dr (1) · Marlene P Freeman, M.D. (1) · Min Tze Liong, Prof.Dr (1) · Paul Myles, MD (1) · Reginald Peters, MD (1)
2017 (1), R25MH112473 (1)